| ²é¿´: 2958 | »Ø¸´: 5 | |||
cuiyubin476½ð³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾ÇóÖú¡¿Ö×ÁöÁÙ´²Ïà¹Ø×¨ÒµÊõÓïÓ¢ÎÄ·Òë ÒÑÓÐ5È˲ÎÓë
|
|
ÇóÖúÖ×ÁöÁÙ´²Ïà¹Ø×¨ÒµÊõÓïÓ¢ÎÄ·Ò룺 overall response »òÕß overall remission £¨OR£© complete remission »òÕßcomplete response (CR) partial remission »òÕßpartial response £¨PR) disease progression progression disease £¨PD) time to progression»òTTP median TTP stable disease £¨SD) extended time to disease progression progression-free survival £¨PFS) median PFS overall suvival £¨OS£© objective response confirmed complete remission unconfirmed complete remission »òCRu confirmed and unconfirmed remissions median duration of response relapsed or refractory aggressive non-Hodgkin¡¯s lymphoma |
» ²ÂÄãϲ»¶
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ106È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Çó¾§ÌåÉú³¤Ïà¹Ø·½ÏòרҵÈËÊ¿·Ò루Ïà¹Ø×¨ÒµÊõÓï±í´ï׼ȷ£© ¶àл°¡£¡
ÒѾÓÐ5È˻ظ´
ÖпÆÔº»¯Ñ§ÀàרҵӢÎÄÎÄÏ×·Òë¶¼¿¼Ê²Ã´£¿
ÒѾÓÐ5È˻ظ´
ÕâЩ·Òë¹ýÀ´µÄÕýÈ·ÊõÓï ºÍÄǸö¾ßÌ庬Òå
ÒѾÓÐ4È˻ظ´
ÒÑ»ñÁÙ´²Åú¼þµÄÔ½ø¿ÚÒ©Æ·×¢²áÉ걨×ÊÁÏ£¬²¿·Ö×ÊÁÏÓ¢ÎÄδ·Ò룬ÔõôҲ»ñÅúÁËÄØ£¿
ÒѾÓÐ6È˻ظ´
Çó¸ßÊÖ½«ÒÔÏÂcomputational method·Òë³ÉÖÐÎÄ£¬×¨ÒµÊõÓïÌ«¶à²»ÖªµÀÔõô·Òë
ÒѾÓÐ11È˻ظ´
ÓÐľÓÐͬѧ֪µÀ±È½ÏºÃµÄרҵÊõÓï·ÒëÈí¼þÄØ£¨Ó¢->ÖУ©
ÒѾÓÐ4È˻ظ´
Ò»¸öÊõÓïÓÐNÖÖ·Ò룬¾¿¾¹ÄÄÒ»ÖÖÊÇÕýÈ·µÄÄØ£¿
ÒѾÓÐ4È˻ظ´
ÇóÖúÉúÎﻯѧרҵһƪӢÎÄÎÄÏ×Èô¸É¾ä×ÓµÄÖÐÎÄ·Òë
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿Ò»Ð©ÊõÓïµÄ·ÒëºÍÇø±ð
ÒѾÓÐ7È˻ظ´
Çó¸ßÊÖ°ïÎÒ·ÒëÕâÒ»¶Î£¬ÓкܶàרҵÊõÓÉúÃü¿ÆÑ§Õâ¿éµÄ³æ×ÓÓ¦¸ÃºÜÊìϤ
ÒѾÓÐ4È˻ظ´
Ò»¶ÎÓ¢ÎÄ·Ò룬±È½Ï¶àµÄÉúÎïרҵÃû´Ê£¬Ð»Ð»°¡£¡
ÒѾÓÐ1È˻ظ´

yexueyan
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1009.8
- Ìû×Ó: 461
- ÔÚÏß: 24.6Сʱ
- ³æºÅ: 306771
- ×¢²á: 2006-12-16
- ÐÔ±ð: MM
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
¡ï ¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
ľЦЦ(½ð±Ò+2):¶àл·ÖÏí 2010-12-21 16:49:56
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
ľЦЦ(½ð±Ò+2):¶àл·ÖÏí 2010-12-21 16:49:56
|
overall response »òÕß overall remission £¨OR: Ö×ÁöµÄÕûÌå·´Ó¦£¬°üÀ¨Ä¿±êËðÉ˺ͷÇÄ¿±êËðÉ˵Ľá¹û complete remission »òÕßcomplete response (CR)£º ÊÇָĿ±êËðÉË»ò·ÇÄ¿±êËðÉËÍêÈ«Ïûʧ£¬¾ÍÊÇÖ¸Ö×ÁöÏûʧ partial remission »òÕßpartial response £¨PR)£º ÊÇָĿ±êËðÉË»ò·ÇÄ¿±êËðÉ˲¿·ÖÏûʧ£¬Ò»°ãÒÔÖ×Áö´óС¼õÉÙ´óÓÚµÈÓÚ20%Ϊ·Ö½çµã disease progression progression disease £¨PD)£º ÊÇÖ¸Ö×ÁöµÄ¶ñ»¯ time to progression»òTTP median TTP stable disease £¨SD)£º ÊÇָĿ±êËðÉË»ò·ÇÄ¿±êËðÉ˵ÄÔö´ó»ò¼õÉÙÎȶ¨ ²»ÖªµÀÂ¥Ö÷ÒªÖªµÀÕâЩ×öʲô£¬ ºÇºÇ ÎÒÔÚ×öÓйØÖ×ÁöµÄÏîÄ¿£¬ÕâЩ¾ÍÊÇÖ×ÁöÆÀ¼ÛÖбȽÏÖØÒªµÄÖ¸±ê¡£ |
2Â¥2010-12-21 16:04:31
cuiyubin476
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ½ð±Ò: 735.2
- ºì»¨: 3
- Ìû×Ó: 381
- ÔÚÏß: 128.4Сʱ
- ³æºÅ: 270824
- ×¢²á: 2006-08-06
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢

3Â¥2010-12-21 22:42:27
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24630.1
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.5Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
koria0727(½ð±Ò+1):¶àл²ÎÓë¡£ 2010-12-22 10:25:26
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
koria0727(½ð±Ò+1):¶àл²ÎÓë¡£ 2010-12-22 10:25:26
|
progression-free survival £¨PFS)ÎÞ½øÕ¹´æ»î median PFS overall suvival £¨OS£©×ÜÌå´æ»î objective responseÄ¿±êÓ¦´ð confirmed complete remissionÈ·Ö¤ÍêÈ«»Ö¸´ unconfirmed complete remission »òCRu confirmed and unconfirmed remissions median duration of responseÓ¦´ð³ÖÐøÊ±¼äÖÐλÊý relapsed or refractory aggressive non-Hodgkin¡¯s lymphoma ¸´·¢½øÕ¹ÐÔ·Ç»ôÆæ½ðÁܰÍÁö ¹©Â¥Ö÷²Î¿¼¡£ |
4Â¥2010-12-22 09:15:11
wnting
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 12556.2
- Ìû×Ó: 340
- ÔÚÏß: 119.1Сʱ
- ³æºÅ: 423361
- ×¢²á: 2007-07-21
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
¡ï ¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
caoyuan521(½ð±Ò+2):лл²ÎÓ룡 2010-12-22 23:02:53
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
caoyuan521(½ð±Ò+2):лл²ÎÓ룡 2010-12-22 23:02:53
|
overall response »òÕß overall remission £¨OR£© ×Ü»º½âÂÊ complete remission »òÕßcomplete response (CR) ÍêÈ«»º½â partial remission »òÕßpartial response £¨PR) ²¿·Ö»º½â disease progression ½øÕ¹ progression disease £¨PD) ½øÕ¹ time to progression»òTTP £¨Ö×Áö£©½øÕ¹Ê±¼ä median TTP ÖÐλ½øÕ¹Ê±¼ä stable disease £¨SD) Îȶ¨ extended time to disease progression ¼²²¡½øÕ¹³ÖÐøÊ±¼ä progression-free survival £¨PFS) ÎÞ½øÕ¹Éú´æÆÚ£¨»òʱ¼ä£© median PFS ÖÐλÎÞ½øÕ¹Éú´æÆÚ overall suvival £¨OS£© ×ÜÉú´æÆÚ objective response ¿Í¹ÛÁÆÐ§ confirmed complete remission È·ÈϵÄÍêÈ«»º½â£¨ÓÐ4ÖܺóµÄÆÀ¹ÀÈ·ÈÏ£© unconfirmed complete remission »òCRu δȷÈϵÄÍêÈ«»º½â confirmed and unconfirmed remissions È·ÈÏ»òδȷÈϵÄÍêÈ«»º½â median duration of response ÖÐλ»º½âʱ¼ä relapsed or refractory aggressive non-Hodgkin¡¯s lymphoma ÄÑÖλò¸´·¢µÄ½øÕ¹ÐÔ·Ç»ôÆæ½ðÁܰÍÁö |
5Â¥2010-12-22 16:04:49
|
6Â¥2012-11-14 11:04:25













»Ø¸´´ËÂ¥